Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

Rhea-AI Summary

Synthetic Biologics (NYSE American: SYN) announced its participation in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, taking place virtually and in New York City from August 8-9, 2022. The company is focused on developing therapeutics for diseases with high unmet needs. It recently acquired VCN Biosciences, enhancing its capabilities in cancer treatment through its lead candidate VCN-01. Other key products include SYN-004, aimed at preventing microbiome damage, and SYN-020, a formulation of intestinal alkaline phosphatase.

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s management will participate in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, to be held virtually and in New York City from August 8-9, 2022.

BTIG hosted events are intended for prospective and existing BTIG clients only. To schedule a meeting with the Company, please contact your BTIG representative.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company recently consummated the acquisition of VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

For further information, please contact:

Investor Relations:

Chris Calabrese

LifeSci Advisors, LLC

ccalabrese@lifesciadvisors.com

917-680-5608

FAQ

When is Synthetic Biologics participating in the BTIG Biotechnology Conference?

Synthetic Biologics will participate in one-on-one investor meetings at the BTIG Biotechnology Conference on August 8-9, 2022.

What is the focus of Synthetic Biologics?

Synthetic Biologics focuses on developing therapeutics for diseases with high unmet needs, including cancer and microbiome-related conditions.

What is VCN-01 developed by Synthetic Biologics?

VCN-01 is an oncolytic adenovirus designed to selectively replicate within tumor cells and enhance the effectiveness of cancer treatments.

What are the key products offered by Synthetic Biologics?

The main products include VCN-01 for cancer treatment, SYN-004 to prevent microbiome damage, and SYN-020, which is intended for local GI and systemic diseases.

How can investors schedule meetings with Synthetic Biologics at the conference?

Investors can schedule meetings by contacting their BTIG representative.